We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker.
- Authors
Agenor de Araújo, Rogério; Cordero da Luz, Felipe Andrés; da Costa Marinho, Eduarda; Piqui Nascimento, Camila; de Andrade Marques, Lara; Ribeiro Delfino, Patrícia Ferreira; Antonioli, Rafael Mathias; Jeha Araújo, Breno; Araújo Lemos da Silva, Ana Cristina; Gonçalves dos Reis Monteiro, Maria Luiza; Neto, Morun Bernardino; Barbosa Silva, Marcelo José
- Abstract
Background: Epidermal growth factor receptor (EGFR) overexpression has been considered a poor prognostic factor in breast cancer. Methodology: A prospective study of 206 women with breast cancer analysed by stages (I, II, III and IV) and by immunohistochemical subtype (Luminal A, Luminal B, HER2+ and triple-negative (TN)); 89 healthy controls with normal recent mammography were included. The EGFR measured in the serum (sEGFR) was detected by the Enzyme- Linked Immunosorbent Assay (ELISA) method (R&D Systems kit DY231) collected by blood before any treatment in patients. Kaplan--Meier method and Cox regression were carried out to obtain the prognostic value, considering significance if p < 0.05. Results: With a median follow-up of 36.6 months, 47 deaths occurred. Multivariable Cox regression showed difference of overall survival (OS) associated with sEGFR levels (sEGFR ≤ or > 47.8 ng/mL) in patients with TN cancers, but not of Luminal A, Luminal B or HER2+ subtypes; adjusted by stage, the death risk increased by approximately 415% [hazard ratio (HR): 5.149 (1.900-13.955), p = 0.001] for patients with sEGFR > 47.8 ng/mL compared to patients with a lower sEGFR value. There was no significant correlation of sEGFR with staging, histological tumour grade (G1/G2/G3), Ki67 (< or ≥14%) or body mass index. Conclusions: Increased sEGFR expression in patients with TN tumours is a significant predictor of lower OS and its quantification is inexpensive and straightforward.
- Subjects
EPIDERMAL growth factor receptors; PROGNOSIS; CANCER prognosis; BODY mass index
- Publication
Ecancermedicalscience, 2022, Vol 16, Issue 1415-1493, p1
- ISSN
1754-6605
- Publication type
Article
- DOI
10.3332/ecancer.2022.1431